TRANSCODE THERAPEUTICS INC (RNAZ)

Curious about the stocks that are showing activity after the closing bell on Thursday?

Which stocks are moving after the closing bell on Thursday?

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors...

TransCode Therapeutics Reports 2023 Results; Provides Business Update

TransCode Therapeutics Reports 2023 Results; Provides Business Update

TransCode Therapeutics Reports 2023 Results; Provides Business Update...

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer...

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment...

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Highlights TTX-MC138’s Path from Target Discovery to the Clinic

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress...

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to get into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning!

Transcode Therapeutics regains compliance with Nasdaq listing rules (NASDAQ:RNAZ)

TransCode Therapeutics regains compliance with Nasdaq's minimum stockholders' equity requirement, ensuring continued listing.

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement, Continued Listing on the Nasdaq Stock Market ...

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer...

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

TransCode Therapeutics closes public offering...

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering...

TransCode Therapeutics announces retirement of CEO (NASDAQ:RNAZ)

TransCode Therapeutics announces retirement of co-founder and CEO Michael Dudley, CFO Tom Fitzgerald becomes interim CEO.

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses, Increased Focus on Planned Phase 1 Clinical Trial; Retirement of CEO ...

TransCode Therapeutics announces 1-for-40 reverse stock split (NASDAQ:RNAZ)

TransCode Therapeutics announces a 1-for-40 reverse stock split, effective Jan. 16, 2024.

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

TransCode Announces Reverse Stock Split...

TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives

Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic Disease

TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives

An Open Letter to Shareholders of TransCode Therapeutics, Inc....

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer...

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating...